The innate resistance of these cancers to CDK4/6 inhibitor monotherapy may relate to the over-expression of cyclin E, which could continue driving the cell cycle in the presence of CDK4/6 inhibition (Table 2) [20]. Here, CDK4 is linked to cancer.